Aussie Biotech Biota Closer To Resolution With GSK On Relenza Suit
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Biota Holdings' lawsuit with GlaxoSmithKline over antiviral influenza vaccine Relenza (zanamivir) is getting closer to resolution, the Melbourne, Australia-based biotech told PharmAsia News
You may also be interested in...
GSK’s Pre-Pandemic Flu Vaccine To Get Priority Review In Japan
TOKYO - Reflecting its growing concerns about new types of influenza outbreaks, Japan's Ministry of Health, Labor and Welfare will conduct a priority review of GlaxoSmithKline K.K.'s pre-pandemic vaccine, a GSK spokesman and ministry officials said Sept. 5
GSK’s Pre-Pandemic Flu Vaccine To Get Priority Review In Japan
TOKYO - Reflecting its growing concerns about new types of influenza outbreaks, Japan's Ministry of Health, Labor and Welfare will conduct a priority review of GlaxoSmithKline K.K.'s pre-pandemic vaccine, a GSK spokesman and ministry officials said Sept. 5
Aussie Biotech Biota Completes Phase II Trials for Relenza Follow-On; Phase III To Be Conducted In Japan, Taiwan, Hong Kong and Korea
PERTH, Australia - Australian biotech Biota completed Phase II trials for its second-generation influenza compound CS-8958; the trials successfully met all endpoints, the company announced July 31